GLYCO-IBD: Glycans as new immunomodulators in inflammatory bowel disease: An opportunity for new therapeutic strategies. (Q2905968): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 85.0 percentage) |
(Changed an Item: Import item from Portugal) |
||||||
| Property / priority axis | |||||||
| Property / priority axis: Strengthening research, technological development and innovation (OT1) / rank | |||||||
Normal rank | |||||||
| Property / co-financing rate | |||||||
85.0 percent
| |||||||
| Property / co-financing rate: 85.0 percent / rank | |||||||
Normal rank | |||||||
Revision as of 01:18, 5 November 2022
Project Q2905968 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | GLYCO-IBD: Glycans as new immunomodulators in inflammatory bowel disease: An opportunity for new therapeutic strategies. |
Project Q2905968 in Portugal |
Statements
166,566.0 Euro
0 references
195,960.0 Euro
0 references
85.0 percent
0 references
1 July 2016
0 references
31 December 2019
0 references
IPATIMUP-INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO
0 references
Q2993205 (Deleted Item)
0 references
Identifiers
POCI-01-0145-FEDER-016601
0 references